APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR T-Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CAR T-Cell Therapy Market Analysis and Forecast 2026-2032

29 December 2025194 pages

Choose your research edition.

Industry ResearchCAR T-Cell Therapy Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR T-Cell Therapy Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CAR T-Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR T-Cell Therapy Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR T-Cell Therapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global CAR T-Cell Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CAR T-Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CAR T-Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CAR T-Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CAR T-Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CAR T-Cell Therapy include J & J, Novartis, Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), JW Therapeutics, Gilead Sciences, FOSUNKite, Celyad(Pipeline) and Cellectis(Pipeline), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CAR T-Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CAR T-Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for CAR T-Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CAR T-Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CAR T-Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CAR T-Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

CAR T-Cell Therapy Segment by Company

J & J

Novartis

Sorrento Therapeutics(Pipeline)

Mustang Bio(Pipeline)

JW Therapeutics

Gilead Sciences

FOSUNKite

Celyad(Pipeline)

Cellectis(Pipeline)

CARsgen Therapeutics (Pipeline)

Bristol-Myers Squibb

Bluebird Bio(Pipeline)

Autolus Therapeutics(Pipeline)

Allogene Therapeutics(Pipeline)

CAR T-Cell Therapy Segment by Type

CD19 - Targeted

BCMA - Targeted

CAR T-Cell Therapy Segment by Application

Lymphoma

Multiple Myeloma

CAR T-Cell Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CAR T-Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CAR T-Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR T-Cell Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CAR T-Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CD19 - Targeted Major Player Table 3. BCMA - Targeted Major Player Table 4. Global CAR T-Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Lymphoma Major Player Table 6. Multiple Myeloma Major Player Table 7. CAR T-Cell Therapy Industry Trends Table 8. CAR T-Cell Therapy Industry Drivers Table 9. CAR T-Cell Therapy Industry Opportunities and Challenges Table 10. CAR T-Cell Therapy Industry Restraints Table 11. Global CAR T-Cell Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global CAR T-Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 13. Global CAR T-Cell Therapy Market Share by Region (2021-2026) Table 14. Global CAR T-Cell Therapy Market Size by Region (2027-2032) & (US$ Million) Table 15. Global CAR T-Cell Therapy Market Share by Region (2027-2032) Table 16. Global CAR T-Cell Therapy Revenue by Players (US$ Million) & (2021-2026) Table 17. Global CAR T-Cell Therapy Revenue Market Share by Players (2021-2026) Table 18. Global CAR T-Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global CAR T-Cell Therapy Key Players Headquarters & Area Served Table 20. Global CAR T-Cell Therapy Players, Product Type & Application Table 21. Global CAR T-Cell Therapy Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global CAR T-Cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global CAR T-Cell Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global CAR T-Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 26. Global CAR T-Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 27. Global CAR T-Cell Therapy Revenue Market Share by Type (2021-2026) Table 28. Global CAR T-Cell Therapy Revenue Market Share by Type (2027-2032) Table 29. Global CAR T-Cell Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CAR T-Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 31. Global CAR T-Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 32. Global CAR T-Cell Therapy Revenue Market Share by Application (2021-2026) Table 33. Global CAR T-Cell Therapy Revenue Market Share by Application (2027-2032) Table 34. J & J Company Information Table 35. J & J Business Overview Table 36. J & J CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. J & J CAR T-Cell Therapy Product Portfolio Table 38. J & J Recent Development Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Novartis CAR T-Cell Therapy Product Portfolio Table 43. Novartis Recent Development Table 44. Sorrento Therapeutics(Pipeline) Company Information Table 45. Sorrento Therapeutics(Pipeline) Business Overview Table 46. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio Table 48. Sorrento Therapeutics(Pipeline) Recent Development Table 49. Mustang Bio(Pipeline) Company Information Table 50. Mustang Bio(Pipeline) Business Overview Table 51. Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio Table 53. Mustang Bio(Pipeline) Recent Development Table 54. JW Therapeutics Company Information Table 55. JW Therapeutics Business Overview Table 56. JW Therapeutics CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. JW Therapeutics CAR T-Cell Therapy Product Portfolio Table 58. JW Therapeutics Recent Development Table 59. Gilead Sciences Company Information Table 60. Gilead Sciences Business Overview Table 61. Gilead Sciences CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Gilead Sciences CAR T-Cell Therapy Product Portfolio Table 63. Gilead Sciences Recent Development Table 64. FOSUNKite Company Information Table 65. FOSUNKite Business Overview Table 66. FOSUNKite CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. FOSUNKite CAR T-Cell Therapy Product Portfolio Table 68. FOSUNKite Recent Development Table 69. Celyad(Pipeline) Company Information Table 70. Celyad(Pipeline) Business Overview Table 71. Celyad(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Celyad(Pipeline) CAR T-Cell Therapy Product Portfolio Table 73. Celyad(Pipeline) Recent Development Table 74. Cellectis(Pipeline) Company Information Table 75. Cellectis(Pipeline) Business Overview Table 76. Cellectis(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio Table 78. Cellectis(Pipeline) Recent Development Table 79. CARsgen Therapeutics (Pipeline) Company Information Table 80. CARsgen Therapeutics (Pipeline) Business Overview Table 81. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio Table 83. CARsgen Therapeutics (Pipeline) Recent Development Table 84. Bristol-Myers Squibb Company Information Table 85. Bristol-Myers Squibb Business Overview Table 86. Bristol-Myers Squibb CAR T-Cell Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio Table 88. Bristol-Myers Squibb Recent Development Table 89. Bluebird Bio(Pipeline) Company Information Table 90. Bluebird Bio(Pipeline) Business Overview Table 91. Bluebird Bio(Pipeline) CAR T-Cell Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio Table 93. Bluebird Bio(Pipeline) Recent Development Table 94. Autolus Therapeutics(Pipeline) Company Information Table 95. Autolus Therapeutics(Pipeline) Business Overview Table 96. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio Table 98. Autolus Therapeutics(Pipeline) Recent Development Table 99. Allogene Therapeutics(Pipeline) Company Information Table 100. Allogene Therapeutics(Pipeline) Business Overview Table 101. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio Table 103. Allogene Therapeutics(Pipeline) Recent Development Table 104. North America CAR T-Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 105. North America CAR T-Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 106. North America CAR T-Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 107. North America CAR T-Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 108. North America CAR T-Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America CAR T-Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 110. North America CAR T-Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 111. Europe CAR T-Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe CAR T-Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe CAR T-Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe CAR T-Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe CAR T-Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Europe CAR T-Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 117. Europe CAR T-Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 118. China CAR T-Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 119. China CAR T-Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 120. China CAR T-Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 121. China CAR T-Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia CAR T-Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 123. Asia CAR T-Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 124. Asia CAR T-Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 125. Asia CAR T-Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia CAR T-Cell Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Asia CAR T-Cell Therapy Revenue by Region (US$ Million) & (2021-2026) Table 128. Asia CAR T-Cell Therapy Revenue by Region (US$ Million) & (2027-2032) Table 129. SAMEA CAR T-Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 130. SAMEA CAR T-Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 131. SAMEA CAR T-Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 132. SAMEA CAR T-Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 133. SAMEA CAR T-Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. SAMEA CAR T-Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 135. SAMEA CAR T-Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. CAR T-Cell Therapy Image Figure 2. Global CAR T-Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CAR T-Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. CD19 - Targeted Image Figure 5. BCMA - Targeted Image Figure 6. Global CAR T-Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CAR T-Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Lymphoma Image Figure 9. Multiple Myeloma Image Figure 10. Global CAR T-Cell Therapy Market Size (US$ Million) & (2021-2032) Figure 11. Global CAR T-Cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global CAR T-Cell Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global CAR T-Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global CAR T-Cell Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global CAR T-Cell Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global CAR T-Cell Therapy Revenue Market Share by Type (2021-2032) Figure 18. Global CAR T-Cell Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global CAR T-Cell Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global CAR T-Cell Therapy Revenue Market Share by Application (2021-2032) Figure 21. North America CAR T-Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America CAR T-Cell Therapy Revenue Share by Type (2021-2032) Figure 23. North America CAR T-Cell Therapy Revenue Share by Application (2021-2032) Figure 24. North America CAR T-Cell Therapy Revenue Share by Country (2021-2032) Figure 25. United States CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe CAR T-Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe CAR T-Cell Therapy Revenue Share by Type (2021-2032) Figure 30. Europe CAR T-Cell Therapy Revenue Share by Application (2021-2032) Figure 31. Europe CAR T-Cell Therapy Revenue Share by Country (2021-2032) Figure 32. Germany CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China CAR T-Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China CAR T-Cell Therapy Revenue Share by Type (2021-2032) Figure 42. China CAR T-Cell Therapy Revenue Share by Application (2021-2032) Figure 43. Asia CAR T-Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia CAR T-Cell Therapy Revenue Share by Type (2021-2032) Figure 45. Asia CAR T-Cell Therapy Revenue Share by Application (2021-2032) Figure 46. Asia CAR T-Cell Therapy Revenue Share by Region (2021-2032) Figure 47. Japan CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA CAR T-Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA CAR T-Cell Therapy Revenue Share by Type (2021-2032) Figure 55. SAMEA CAR T-Cell Therapy Revenue Share by Application (2021-2032) Figure 56. SAMEA CAR T-Cell Therapy Revenue Share by Country (2021-2032) Figure 57. Brazil CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt CAR T-Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • CD19 - Targeted
  • BCMA - Targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • J & J
  • Novartis
  • Sorrento Therapeutics(Pipeline)
  • Mustang Bio(Pipeline)
  • JW Therapeutics
  • Gilead Sciences
  • FOSUNKite
  • Celyad(Pipeline)
  • Cellectis(Pipeline)
  • CARsgen Therapeutics (Pipeline)
  • Bristol-Myers Squibb
  • Bluebird Bio(Pipeline)
  • Autolus Therapeutics(Pipeline)
  • Allogene Therapeutics(Pipeline)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CAR T-Cell Therapy Market by Type
  3. 1.2.1 Global CAR T-Cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CD19 - Targeted
  5. 1.2.3 BCMA - Targeted
  6. 1.3 CAR T-Cell Therapy Market by Application
  7. 1.3.1 Global CAR T-Cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Lymphoma
  9. 1.3.3 Multiple Myeloma
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 CAR T-Cell Therapy Market Dynamics
  1. 2.1 CAR T-Cell Therapy Industry Trends
  2. 2.2 CAR T-Cell Therapy Industry Drivers
  3. 2.3 CAR T-Cell Therapy Industry Opportunities and Challenges
  4. 2.4 CAR T-Cell Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CAR T-Cell Therapy Market Perspective (2021-2032)
  2. 3.2 Global CAR T-Cell Therapy Growth Trends by Region
  3. 3.2.1 Global CAR T-Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CAR T-Cell Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global CAR T-Cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CAR T-Cell Therapy Revenue by Players
  2. 4.1.1 Global CAR T-Cell Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CAR T-Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CAR T-Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CAR T-Cell Therapy Key Players Headquarters & Area Served
  7. 4.4 Global CAR T-Cell Therapy Players, Product Type & Application
  8. 4.5 Global CAR T-Cell Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CAR T-Cell Therapy Market CR5 and HHI
  11. 4.6.3 2025 CAR T-Cell Therapy Tier 1, Tier 2, and Tier 3
5 CAR T-Cell Therapy Market Size by Type
  1. 5.1 Global CAR T-Cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CAR T-Cell Therapy Revenue by Type (2021-2032)
  3. 5.3 Global CAR T-Cell Therapy Revenue Market Share by Type (2021-2032)
6 CAR T-Cell Therapy Market Size by Application
  1. 6.1 Global CAR T-Cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CAR T-Cell Therapy Revenue by Application (2021-2032)
  3. 6.3 Global CAR T-Cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 J & J
  2. 7.1.1 J & J Company Information
  3. 7.1.2 J & J Business Overview
  4. 7.1.3 J & J CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 J & J CAR T-Cell Therapy Product Portfolio
  6. 7.1.5 J & J Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis CAR T-Cell Therapy Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Sorrento Therapeutics(Pipeline)
  14. 7.3.1 Sorrento Therapeutics(Pipeline) Company Information
  15. 7.3.2 Sorrento Therapeutics(Pipeline) Business Overview
  16. 7.3.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
  18. 7.3.5 Sorrento Therapeutics(Pipeline) Recent Developments
  19. 7.4 Mustang Bio(Pipeline)
  20. 7.4.1 Mustang Bio(Pipeline) Company Information
  21. 7.4.2 Mustang Bio(Pipeline) Business Overview
  22. 7.4.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
  24. 7.4.5 Mustang Bio(Pipeline) Recent Developments
  25. 7.5 JW Therapeutics
  26. 7.5.1 JW Therapeutics Company Information
  27. 7.5.2 JW Therapeutics Business Overview
  28. 7.5.3 JW Therapeutics CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 JW Therapeutics CAR T-Cell Therapy Product Portfolio
  30. 7.5.5 JW Therapeutics Recent Developments
  31. 7.6 Gilead Sciences
  32. 7.6.1 Gilead Sciences Company Information
  33. 7.6.2 Gilead Sciences Business Overview
  34. 7.6.3 Gilead Sciences CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Gilead Sciences CAR T-Cell Therapy Product Portfolio
  36. 7.6.5 Gilead Sciences Recent Developments
  37. 7.7 FOSUNKite
  38. 7.7.1 FOSUNKite Company Information
  39. 7.7.2 FOSUNKite Business Overview
  40. 7.7.3 FOSUNKite CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 FOSUNKite CAR T-Cell Therapy Product Portfolio
  42. 7.7.5 FOSUNKite Recent Developments
  43. 7.8 Celyad(Pipeline)
  44. 7.8.1 Celyad(Pipeline) Company Information
  45. 7.8.2 Celyad(Pipeline) Business Overview
  46. 7.8.3 Celyad(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Celyad(Pipeline) CAR T-Cell Therapy Product Portfolio
  48. 7.8.5 Celyad(Pipeline) Recent Developments
  49. 7.9 Cellectis(Pipeline)
  50. 7.9.1 Cellectis(Pipeline) Company Information
  51. 7.9.2 Cellectis(Pipeline) Business Overview
  52. 7.9.3 Cellectis(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio
  54. 7.9.5 Cellectis(Pipeline) Recent Developments
  55. 7.10 CARsgen Therapeutics (Pipeline)
  56. 7.10.1 CARsgen Therapeutics (Pipeline) Company Information
  57. 7.10.2 CARsgen Therapeutics (Pipeline) Business Overview
  58. 7.10.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio
  60. 7.10.5 CARsgen Therapeutics (Pipeline) Recent Developments
  61. 7.11 Bristol-Myers Squibb
  62. 7.11.1 Bristol-Myers Squibb Company Information
  63. 7.11.2 Bristol-Myers Squibb Business Overview
  64. 7.11.3 Bristol-Myers Squibb CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio
  66. 7.11.5 Bristol-Myers Squibb Recent Developments
  67. 7.12 Bluebird Bio(Pipeline)
  68. 7.12.1 Bluebird Bio(Pipeline) Company Information
  69. 7.12.2 Bluebird Bio(Pipeline) Business Overview
  70. 7.12.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
  72. 7.12.5 Bluebird Bio(Pipeline) Recent Developments
  73. 7.13 Autolus Therapeutics(Pipeline)
  74. 7.13.1 Autolus Therapeutics(Pipeline) Company Information
  75. 7.13.2 Autolus Therapeutics(Pipeline) Business Overview
  76. 7.13.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
  78. 7.13.5 Autolus Therapeutics(Pipeline) Recent Developments
  79. 7.14 Allogene Therapeutics(Pipeline)
  80. 7.14.1 Allogene Therapeutics(Pipeline) Company Information
  81. 7.14.2 Allogene Therapeutics(Pipeline) Business Overview
  82. 7.14.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
  84. 7.14.5 Allogene Therapeutics(Pipeline) Recent Developments
8 North America
  1. 8.1 North America CAR T-Cell Therapy Revenue (2021-2032)
  2. 8.2 North America CAR T-Cell Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America CAR T-Cell Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America CAR T-Cell Therapy Revenue by Type (2027-2032)
  5. 8.3 North America CAR T-Cell Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America CAR T-Cell Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America CAR T-Cell Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America CAR T-Cell Therapy Revenue by Application (2027-2032)
  9. 8.5 North America CAR T-Cell Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America CAR T-Cell Therapy Revenue by Country
  11. 8.6.1 North America CAR T-Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CAR T-Cell Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America CAR T-Cell Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe CAR T-Cell Therapy Revenue (2021-2032)
  2. 9.2 Europe CAR T-Cell Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe CAR T-Cell Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe CAR T-Cell Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe CAR T-Cell Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe CAR T-Cell Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe CAR T-Cell Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe CAR T-Cell Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe CAR T-Cell Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe CAR T-Cell Therapy Revenue by Country
  11. 9.6.1 Europe CAR T-Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CAR T-Cell Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe CAR T-Cell Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China CAR T-Cell Therapy Revenue (2021-2032)
  2. 10.2 China CAR T-Cell Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China CAR T-Cell Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China CAR T-Cell Therapy Revenue by Type (2027-2032)
  5. 10.3 China CAR T-Cell Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China CAR T-Cell Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China CAR T-Cell Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China CAR T-Cell Therapy Revenue by Application (2027-2032)
  9. 10.5 China CAR T-Cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CAR T-Cell Therapy Revenue (2021-2032)
  2. 11.2 Asia CAR T-Cell Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia CAR T-Cell Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia CAR T-Cell Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia CAR T-Cell Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia CAR T-Cell Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia CAR T-Cell Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia CAR T-Cell Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia CAR T-Cell Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia CAR T-Cell Therapy Revenue by Country
  11. 11.6.1 Asia CAR T-Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CAR T-Cell Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia CAR T-Cell Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CAR T-Cell Therapy Revenue (2021-2032)
  2. 12.2 SAMEA CAR T-Cell Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CAR T-Cell Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CAR T-Cell Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA CAR T-Cell Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CAR T-Cell Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CAR T-Cell Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CAR T-Cell Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA CAR T-Cell Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CAR T-Cell Therapy Revenue by Country
  11. 12.6.1 SAMEA CAR T-Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CAR T-Cell Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CAR T-Cell Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst